Chemistry

   

Rasagiline Hemitartrate: Synthesis, Characterization and RP-HPLC Validation for Its Estimation in Bulk Form

Authors: Muvvala S. Sudhir, Ratnakaram Venkata Nadh

Objectives: To develop a reverse phase high performance liquid chromatographic method for validation and quantitative estimation of the synthesized drug rasagiline hemitartrate in bulk form. Methods: Rasagiline hemitartrate was synthesized and characterized by spectral (Infrared, Proton Nuclear Magnetic Resonance and Mass) as well as elemental analysis. Chromatographic separation was conducted on Agilent TC-C18 (2504.6mm,5 mm) columnat ambient temperature using mixture of 20mM potassium dihydrogen orthophosphate buffer (pH 7.0): methanol and acetonitrile in the ratio (30:30:40 v/v) as a mobile phase and at a flow rate of 1.0 mL/min, while UV detection was performed at 285 nm. In addition to LOD and LOQ, other analytical parameters viz., linearity, precision, accuracy, ruggedness and robustness were detected by following the ICH (International Conference on Harmonization) guidelines. Results: The retention time for rasagiline hemitartrate was found to be 4.30 0.05 min. The method was found to be linear in the range of 10e50 mg/mL. The limit of detection and quantization for rasagiline hemitartrate are found to be 0.651 and 1.972 mg/mL respectively. Analytical recovery was 100.47%. The percentage RSD for precision and accuracy of the method was found to be less than 2%. Correlation coefficient was found to be 0.9952. Conclusion: In this study, simple, sensitive, accurate and reliable RP-HPLC method was developed and validated as per the ICH guidelines for the determination of the synthesized drug rasagiline hemitartrate in bulk form.

Comments: 6 Pages. OK

Download: PDF

Submission history

[v1] 2019-05-19 05:46:36

Unique-IP document downloads: 0 times

Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus